Ssie (Yghj), A Cell-Associated And Secreted Lipoprotein Of Neonatal Septicemic Escherichia Coli, Induces Toll-Like Receptor 2-Dependent Macrophage Activation And Proinflammation Through Nf-Kappa B And Map Kinase Signaling

SsIE (YghJ), a cell surface-associated and secreted lipoprotein, was identified as a potential vaccine candidate for extraintestinal pathogenic Escherichia coli, providing nearly complete protection from sepsis in a mouse model. We earlier found that SsIE from neonatal septicemic E. coli could trigger the secretion of various proinfiammatory cytokines in murine macrophages, the signaling pathway of which is still obscure. In this study, we showed that SsIE specifically binds to Tolllike receptor 2 (TLR2)/TLR1 heterodimers and recruits downstream adaptors MyD88, TIRAP, and TRAF6. In addition, SsIE stimulates nuclear translocation of NF-kappa B and activates different mitogen-activated protein (MAP) kinase signaling cascades specific to the secretion of each cytokine in murine macrophages, which becomes impaired in TLR2 small interfering RNA (siRNA)-transfected cells and in cells blocked with a monoclonal antibody (MAb) against TLR2, suggesting the involvement of TLR2 in NF-kappa B and MAP kinase activation and subsequent cytokine secretion. Furthermore, our study is the first to show that SsIE can stimulate TLR2-dependent production of other proinflammatory hallmarks, such as reactive nitrogen and oxygen species as well as type 1 chemokines, which contribute to the anti-infection immune response of the host. Also, the overexpression of major histocompatibility complex class II (MHC II) and other costimulatory molecules (CD80 and CD86) in macrophages essentially indicates that SsIE promotes macrophage activation and M1 polarization, which are crucial in framing the host's innate immune response to this protein, and hence, SsIE could be a potent immunotherapeutic target against E. coli sepsis.